The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,425 | - |
| Stock-based compensation | 27 | 136 |
| Net loss | - | -7,449 |
| Amortization of debt issuance costs | 40 | 40 |
| Amortization of right of use assets | -2 | 59 |
| Default on convertible debt | 90 | - |
| Loss on convertible debt conversions | 43 | - |
| Depreciation | 9 | 14 |
| Change in fair value of warrant liability | 817 | -394 |
| Change in fair value of derivative liability | 343 | - |
| Prepaid drug product | 1,200 | -600 |
| Interest payable | - | 51 |
| Other current assets | 2,623 | -1,283 |
| Accounts payable and accrued expenses | 447 | 4,122 |
| Lease liabilities | 2 | -58 |
| Net cash used in operating activities | 0 | -1,596 |
| Net proceeds from exercise of pre-funded warrants | 0 | 1 |
| Proceeds from promissory notes | 0 | 422 |
| Net cash provided by financing activities | 0 | 423 |
| Net increase (decrease) in cash | 0 | -1,173 |
| Cash and cash equivalents at beginning of period | 1,173 | - |
| Cash and cash equivalents at end of period | 0 | - |
BIO-PATH HOLDINGS, INC. (BPTH)
BIO-PATH HOLDINGS, INC. (BPTH)